Business Wire

BACARDI-LIMITED

13.2.2020 14:17:09 CET | Business Wire | Press release

Share
Bacardi Limited Paves the Way For A Good Spirited Future

Family-owned Bacardi Limited has been doing the right thing for its people, its community and the planet more than 158 years. Today, the company released its fiscal year 2019 Good Spirited Corporate Responsibility (CR) Report to provide open and transparent communications in how it’s championing commitments within its CR pillars of marketplace , people , environment , responsible sourcing , and philanthropy and community investment . From responsible drinking efforts, to driving a positive and diverse culture, to hurricane disaster relief and reducing the impact on natural resources, the Good Spirited Corporate Responsibility Report outlines progress in fiscal year 2019, alongside commitments for the future. This marks the 12th annual CR report issued by privately-held Bacardi Limited.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005465/en/

“Being family-owned for seven generations allows us to stay true to our values of being fearless to innovate, behaving like family to each other and our communities, and exhibiting founders mentality in always doing the right thing -- particularly towards making the world a more sustainable, safe and transparent place,” says Rick Wilson, Senior Vice President of Corporate Responsibility at Bacardi. “It’s extremely gratifying to see us achieve key milestones, in some cases ahead of time, and to continuously pursue new goals and set higher standards for the future.”

The report outlines the overall marketplace for spirits and addresses the responsibility Bacardi has in promoting responsible drinking practices and targeting our marketing only to legal age drinkers. With the evolution of digital marketing, the company has doubled down efforts to enforce safeguards to limit minors from seeing alcohol marketing online. Bacardi has achieved 79% compliance in establishing these safeguards with an aim to be 100% compliant by 2020. Bacardi has also been an early mover in the space of nutrition transparency, with the launch of a Bacardi nutrition website in key markets giving consumers more information about what they’re drinking including calories and allergens.

The vibrant, warm and entrepreneurial culture at Bacardi is reflected in the exceptional employee engagement with the global internal survey showing 89% of employees saying they are “proud to work for the company.” External perception of the company is also positive as Bacardi Limited was named among the most reputable companies in the world as part of the annual Global RepTrak® 100 list compiled by the Reputation Institute (RI) and published in Forbes. Ranked at #87, Bacardi Limited climbed two spots and has made the annual global list seven consecutive times.

Bacardi believes in the inherent value that can be created when you bring together a diverse and inclusive community and workplace. Helping female talent at Bacardi, and within our community, is among the many causes championed by the company through its Global Reflections program. The company has made considerable headway with women making up 44% of North America and 40% of Europe – which represent the two largest regions of the business. In addition, 37% of the leadership positions in the company were held by women in fiscal year 2019 and the company continues to work towards narrowing the gender gap.

Bacardi continues to push the boundaries with aspirations to be the world’s most environmentally responsible global spirits company. Finding a second life for all waste is a priority and the company’s production facilities have achieved 99.6% of waste diversion. Despite increases in production, the company has been able to reduce greenhouse gas emissions from operations by 20% and cut water consumption by almost 10% through efficiencies in assets utilization. It is also committed to the long-term sustainability and responsible sourcing of sugarcane, agave, wheat, botanicals, and other natural resources needed to craft its world-class premium products. Already 98.4% of the sugarcane-derived products used in BACARDÍ® rums are sourced from suppliers certified by Bonsucro, with the goal of reaching 100% by the end of fiscal year 2020, three years ahead of initial targets. The company also achieved ECOCERT certification for 50% of botanicals for BOMBAY SAPPHIRE® gin with a goal to certify 100% of the botanicals in the coming year. With an eye for the future and always pushing to do greater good, Bacardi has defined a long-term plan to reduce greenhouse gas emissions by 20% and water consumption by 25% by fiscal year 2024.

Going beyond the company to care for the community is part of the DNA at Bacardi since its inception in 1862. Bacardi, together with Mercy Corp, continues to support the long-term recovery efforts in Puerto Rico, where BACARDÍ rum is produced, after devastation from Hurricanes Maria and Irma in 2017, providing habitat rehabilitation, financial grants, business training, and marketing support to 243 businesses on the island.

To read more about Corporate Responsibility within Bacardi, check out the complete FY19 Corporate Responsibility Report, which encompasses April 1, 2018 – March 31, 2019, online https://www.bacardilimited.com/corporate-responsibility/ .

About Bacardi Limited

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka.

Founded more than 158 years ago, in Santiago de Cuba on February 4, 1862, family-owned Bacardi currently employs more than 7,000, operates more than 20 production facilities, including bottling, distilling and manufacturing sites in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Instagram , LinkedIn and Twitter .

Enjoy Responsibly.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye